公开(公告)号：US20180141991A1

公开(公告)日：2018-05-24

申请号：US15735949

申请日：2016-06-12

申请人： Yen-Ta LU ,  Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital

发明人： Yen-Ta LU ,  Chia-Ming CHANG ,  Tsai-Yin WEI

IPC分类号： C07K14/705 ,  A61K38/17 ,  A61P37/06 ,  A61K47/59 ,  A61K47/64 ,  A61K45/06

CPC分类号： C07K16/2845 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/59 ,  A61K47/643 ,  A61P37/06 ,  C07K14/705 ,  C07K14/70503 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/70

摘要： A method for modulating an immunoresponse includes binding a TREM-like transcript 1 (TLT-1) polypeptide to an immune cell, wherein the binding of the TLT-1 polypeptide to the immune cell suppresses immunoresponse. A method for treating and/or preventing a disease associated with immune hyper-reactivity includes administering the TLT-1 polypeptide to a subject in need thereof.

公开(公告)号：US20170283408A1

公开(公告)日：2017-10-05

申请号：US15512248

申请日：2015-09-17

申请人： YEN-TA LU ,  TZENGE-LIEN SHIH ,  CHIA-MING CHANG ,  TSAI-YIN WEI ,  JEN-WEI LIU

发明人： YEN-TA LU ,  TZENGE-LIEN SHIH ,  CHIA-MING CHANG ,  TSAI-YIN WEI ,  JEN-WEI LIU

IPC分类号： C07D417/04 ,  A61K39/395 ,  A61K45/06 ,  A61K31/4035 ,  A61K31/473 ,  C07D413/04 ,  C07D209/48 ,  C07K16/28 ,  C07D221/14

CPC分类号： C07D417/04 ,  A61K31/4035 ,  A61K31/473 ,  A61K31/635 ,  A61K39/3955 ,  A61K45/06 ,  C07D209/48 ,  C07D221/06 ,  C07D221/14 ,  C07D413/04 ,  C07K16/2818 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention relates to benzoxazole derivatives having the following Formula (I): The compounds of the present invention are found to possess the ability to decrease PD-L1 level, suggesting that the compounds of the invention can be used in cancer immunotherapy and treatment or prevention of sepsis or septic shock.

公开(公告)号：US08491894B2

公开(公告)日：2013-07-23

申请号：US13164137

申请日：2011-06-20

申请人： Yen-Ta Lu ,  I-Fang Tsai

发明人： Yen-Ta Lu ,  I-Fang Tsai

IPC分类号： A61K39/395 ,  A61K39/04 ,  A61K39/00

CPC分类号： C07K16/2896 ,  C07K2317/76

摘要： The present invention discloses a method for inhibiting the growth of Mycobacterium tuberculosis, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of Mycobacterium tuberculosis. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry of Mycobacterium tuberculosis into monocytes, reduce survival of Mycobacterium tuberculosis in monocytes, and kill Mycobacterium tuberculosis effectively.

摘要翻译： 本发明公开了一种抑制结核分枝杆菌生长的方法，包括：施用至少一种可结合细胞的CD13受体的抗CD13抗体或CD13拮抗剂的选择性结合剂抑制结核分枝杆菌感染。 抗CD13抗体的施用可以降低CD13受体的表达水平，抑制结核分枝杆菌进入单核细胞，降低单核细胞结核分枝杆菌的存活，并有效杀死结核分枝杆菌。

公开(公告)号：US08455474B2

公开(公告)日：2013-06-04

申请号：US13041047

申请日：2011-03-04

申请人： Yen-Ta Lu ,  I-Fang Tsai

发明人： Yen-Ta Lu ,  I-Fang Tsai

IPC分类号： A61K31/397 ,  A61P31/06

CPC分类号： A61K31/397

摘要： Disclosed is a method for treating a symptom of M. tuberculosis infection in a subject, comprising administering the patient with an effective amount of (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)zetidin-2-one (EZETIMIBE). In the preferred embodiments, EZETIMIBE is capable of significantly inhibiting the survival and proliferation of Mycobacterium tuberculosis in the monocytes. The anti-tuberculous effect of EZETIMIBE is partly through stimulating CD13 leading to monocytes activation and thus bacterial killing of Mycobacterium tuberculosis, and partly through depleting the intracellular nutrition necessary for the survival of Mycobacterium tuberculosis. It is also proved that EZETIMIBE is capable of directly killing Mycobacterium tuberculosis outside cells.

摘要翻译： 公开了一种治疗受试者结核分枝杆菌感染症状的方法，包括给予患者有效量的（3R，4S）-1-（4-氟苯基）-3 - [（3S）-3-（ 4-（4-羟基苯基）哌啶-2-酮（EZETIMIBE）。 在优选的实施方案中，EZETIMIBE能够显着抑制单核细胞中结核分枝杆菌的存活和增殖。 EZETIMIBE的抗结核作用部分是通过刺激CD13导致单核细胞激活，从而细菌杀死结核分枝杆菌，部分通过消耗结核分枝杆菌存活所需的细胞内营养。 也证明EZETIMIBE能够直接杀死细胞外的结核分枝杆菌。

公开(公告)号：US20120225113A1

公开(公告)日：2012-09-06

申请号：US13041047

申请日：2011-03-04

申请人： Yen-Ta Lu ,  I-Fang Tsai

发明人： Yen-Ta Lu ,  I-Fang Tsai

IPC分类号： A61K9/127 ,  A61K31/397 ,  A61P31/06

CPC分类号： A61K31/397

摘要： Disclosed is a method for treating a symptom of M. tuberculosis infection in a subject, comprising administering the patient with an effective amount of (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)zetidin-2-one (EZETIMIBE). In the preferred embodiments, EZETIMIBE is capable of significantly inhibiting the survival and proliferation of Mycobacterium tuberculosis in the monocytes. The anti-tuberculous effect of EZETIMIBE is partly through stimulating CD13 leading to monocytes activation and thus bacterial killing of Mycobacterium tuberculosis, and partly through depleting the intracellular nutrition necessary for the survival of Mycobacterium tuberculosis. It is also proved that EZETIMIBE is capable of directly killing Mycobacterium tuberculosis outside cells.

摘要翻译： 公开了一种治疗受试者结核分枝杆菌感染症状的方法，包括给予患者有效量的（3R，4S）-1-（4-氟苯基）-3 - [（3S）-3-（ 4-（4-羟基苯基）哌啶-2-酮（EZETIMIBE）。 在优选的实施方案中，EZETIMIBE能够显着抑制单核细胞中结核分枝杆菌的存活和增殖。 EZETIMIBE的抗结核作用部分是通过刺激CD13导致单核细胞激活，从而细菌杀死结核分枝杆菌，部分通过消耗结核分枝杆菌存活所需的细胞内营养。 也证明EZETIMIBE能够直接杀死细胞外的结核分枝杆菌。

公开(公告)号：US20120064624A1

公开(公告)日：2012-03-15

申请号：US13164137

申请日：2011-06-20

申请人： Yen-Ta Lu ,  I-Fang Tsai

发明人： Yen-Ta Lu ,  I-Fang Tsai

IPC分类号： C12N5/0786 ,  C12N5/071

CPC分类号： C07K16/2896 ,  C07K2317/76

摘要： The present invention discloses a method for inhibiting the growth of Mycobacterium tuberculosis, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of Mycobacterium tuberculosis. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry of Mycobacterium tuberculosis into monocytes, reduce survival of Mycobacterium tuberculosis in monocytes, and kill Mycobacterium tuberculosis effectively.

摘要翻译： 本发明公开了一种抑制结核分枝杆菌生长的方法，包括：施用至少一种可结合细胞的CD13受体的抗CD13抗体或CD13拮抗剂的选择性结合剂抑制结核分枝杆菌感染。 抗CD13抗体的施用可以降低CD13受体的表达水平，抑制结核分枝杆菌进入单核细胞，降低单核细胞结核分枝杆菌的存活，并有效杀死结核分枝杆菌。